2006
The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal Of The American College Of Cardiology 2006, 47: 726-733. PMID: 16487836, DOI: 10.1016/j.jacc.2005.09.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina PectorisAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtherosclerosisCaptoprilCardiovascular DiseasesDisease-Free SurvivalDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMyocardial InfarctionRandomized Controlled Trials as TopicRecurrenceStrokeTetrazolesValineValsartanConceptsAngiotensin receptor blockersAcute Myocardial Infarction trialMyocardial Infarction trialAtherosclerotic eventsMyocardial infarctionACE inhibitorsValsartan groupReceptor blockersEnzyme inhibitorsNon-fatal myocardial infarctionAngiotensin-converting enzyme inhibitorAnti-infarction effectSecondary preventive treatmentEffect of valsartanRenin-angiotensin systemBlood pressure differenceEffects of captoprilAcute myocardial infarctionCaptopril groupCombination groupPreventive treatmentLower riskEvidence gapsCaptoprilValsartan
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment